Friday, 29 November 2013

Human embryonic stem cell lines placed on NIH Stem Cell Registry

Scientists at King’s College London announced a few days ago that 16 human embryonic stem cell lines have been approved by the US National Institutes of Health (NIH) and placed on their Stem Cell Registry, making them freely available for federally-funded research in the USA.

The stem cell lines, which carry genes for a variety of hereditary disorders such as Huntington’s disease, spinal muscular dystrophy and cystic fibrosis, are considered to be ideal research tools for designing models to understand disease progression, and ultimately in helping scientists develop new treatments for patients.

King’s is now one of the five biggest providers of disease-specific human embryonic stem cells lines on the NIH Registry, and the largest from the UK. The development is a significant milestone for King’s and keeps the university at the forefront of global research into regenerative medicine.Embryonic stem cell lines are grown from frozen embryos donated by patients undergoing preimplantation genetic diagnosis (PGD) in conjunction with IVF treatment. Unlike ‘adult’ stem cells, embryonic stem cells can differentiate into any type of cell within the body and are considered to be more useful for stem cell-based therapies. Disease-specific stem cell lines are created from embryos found to be affected with genetic disorders and therefore not suitable for implantation, but offer huge potential for research into disease development.

King’s has already developed eight clinical-grade and more than 30 research-grade stem cell lines, which were approved by the UK Stem Cell Steering Committee to be deposited with the UK Stem Cell Bank (UKSCB) and distributed worldwide.

"We are delighted that the NIH has found our lines useful and their procurement and consents in line with the strict guidelines that they have set. This achievement is the culmination of over ten years of painstaking research and consistent belief in the scientific usefulness of these very special cells to improve our understanding of genetic disease processes. This is a huge milestone for King’s, and will allow us to make a major contribution to global stem cell research by having these stem cell lines available to scientists in the USA. These research-grade stem cell lines are essential not only to address basic questions in development and disease, but to test and implement technical improvements in culture conditions that might affect hES cell viability and pluripotency." saidProfessor Peter Braude, Emeritus Professor of Obstetrics and Gynaecology, King’s College London; and former director of the Stem Cell Programme and the Pre-Implantation Genetic Diagnosis Programme, Guy’s and St Thomas’ NHS Foundation Trust.

"I’m delighted that the NIH has accepted our stem cell lines. There are now significant opportunities for US-based researchers to use these lines as tools to test the molecular mechanisms of common diseases, so it’s fantastic that they are now freely available to advance the science of stem cell therapy and regenerative medicine." said Dr Dusko Ilic, Senior Lecturer in Stem Cell Science at King’s College London.

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !

Blog Archive

The owner of this website, http://www.stemcellsfreak.com, is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking http://www.stemcellsfreak.com to Amazon properties including, but not limited to, amazon.com, endless.com, myhabit.com, smallparts.com, or amazonwireless.com.